AbbVie’s Skyrizi becomes first FDA-approved IL-23 inhibitor for Crohn’s diseaseTherapeuticsThe U.S. Food and Drug Administration has awarded its first approval in the specific interleukin-23 inhibitor space for Crohn’s disease to AbbVie’s Skyrizi I (risakizumab-rzaa). Read more June 20, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/05/AbbVie-Subsidiary-Scoops-Up-Soliton-and-Its-Cellulite-Tattoo-Removal-Device-BioSpace-5-11-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-06-20 09:37:102022-06-20 09:37:10AbbVie’s Skyrizi becomes first FDA-approved IL-23 inhibitor for Crohn’s disease